<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025883</url>
  </required_header>
  <id_info>
    <org_study_id>020022</org_study_id>
    <secondary_id>02-DK-0022</secondary_id>
    <nct_id>NCT00025883</nct_id>
  </id_info>
  <brief_title>Leptin to Treat Lipodystrophy</brief_title>
  <official_title>Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of leptin replacement therapy in
      patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss
      of fat cells. They also lack the hormone leptin, which is produced by fat cells. The leptin
      deficiency usually causes high blood lipid (fat) levels and insulin resistance that may lead
      to diabetes. Patients may have hormone imbalances, fertility problems, large appetite, and
      liver disease due to fat accumulation.

      Patients age greater than or equal to 6 months with significant lipodystrophy may be eligible
      for this study. Participants will be admitted to the NIH Clinical Center for 10 days for the
      following studies before beginning 12 months of leptin therapy:

        -  Insulin tolerance test

        -  Ultrasound of the liver and, if abnormalities are found, possibly liver biopsies.

        -  Fasting blood tests

        -  Resting metabolic rate

        -  Magnetic resonance imaging of the liver and other organs, and of muscle and fat.

        -  Pelvic ultrasound in women to detect ovarian cysts.

        -  Estimation of body fat

        -  Oral glucose tolerance test

        -  Intravenous glucose tolerance test

        -  Appetite level and food intake

        -  Hormone function tests

        -  Questionnaires to assess activity and mood

        -  24-hour urine collections

      Additional studies may include blood tests for genetic studies of lipodystrophy, a muscle
      biopsy to study muscle proteins involved in regulating energy expenditure before and after
      leptin replacement, and examination of a surgical specimen (if available) to study molecules
      that may be involved in energy storage and use.

      When the above tests are completed, leptin therapy begins. The drug is injected under the
      skin twice a day for 4 months and then once a day, if feasible. The dose is increased at the
      1- and 2-month visits. Follow-up visits at 1, 2, 4, 6, 8 and 12 months after therapy starts
      include a physical examination, blood tests and a meeting with a dietitian. At the end of 12
      months, all baseline studies described above are repeated. Patients record their symptoms
      weekly throughout the study. Those with diabetes measure their blood glucose levels daily
      before each meal and at bedtime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipoatrophic diabetes is a syndrome characterized by insulin resistance in association with a
      paucity of adipose tissue. Patients with severe lipoatrophy die prematurely, typically from
      the complications of diabetes or liver disease. Experiments with lipoatrophic mice suggest
      that the insulin resistance is caused by the lack of adipose tissue. Adipose tissue normally
      produces leptin, a hormone that increases insulin action. For the last fourteen years, we
      have been studying the extent to which leptin deficiency causes diabetes in lipoatrophic
      patients. In fact, in our initial study we have seen nearly 60% amelioration of fasting
      glucose, triglycerides and free fatty acid levels and about 2% actual decreases from baseline
      HbA1c levels with 4 months of leptin replacement therapy. This response has continued to be
      sustained, as we continue to follow patients that have now received leptin replacement
      therapy for fourteen years.

      This is an open-labeled study. The study monitors the safety and efficacy of recombinant
      methionyl human leptin (A-100) replacement in children and adults. We are looking at the
      long-term effects of leptin replacement on extended therapy. In this long-term replacement
      protocol, we will monitor metabolic control (e.g. glucose, insulin, and triglyceride levels)
      as primary outcome measures. Ancillary studies will evaluate the effect of Metreleptin on
      other hormonal axes, growth and development and on liver pathology.

      We continue to evaluate the efficacy in a broader leptin deficient population of patients
      with lipodystrophy. Current inclusion criteria in patients greater than or equal to 5 years
      include female patients with leptin levels &lt; 12 ng/mL and male patients with leptin levels &lt;
      8 ng/mL. We continue to seek patients who meet these criteria. In children ages 6 months 5
      years, we will use a cut-off leptin level of 6 ng/mL in both genders.

      Patients who are greater than or equal to age 5 years will be evaluated every 6 months during
      the first year of therapy. If no improvements are seen after 6 months of therapy, then the
      study medication may be increased to 150% of the predicted dose (0.09mg/kg/day for males and
      girls less than 10 years of age/ 0.12mg/kg/day for females 10 years of age and older) from 6
      months to 1 year on therapy. If no improvements are seen after increasing to 150% of the
      predicted dose, then the study medication will be withdrawn. If the patient shows
      improvements in his/her metabolic parameters while on leptin, the patient will be invited to
      continue taking the study medication. The investigators will strive for all patients
      responding to leptin to bring their metabolic parameters into the normal range. The maximum
      dose of leptin that will be given is 0.24 mg/kg/day for females 10 and older, and 0.12
      mg/kg/day for males and females less than 10 years of age. After the first year of treatment,
      the patient will be evaluated every 6 months through the second year of treatment, and then
      the study period will end. After two years of treatment, extending the treatment period on an
      annual basis will be the decision of the patient, principal investigator and Bristol-Myers
      Squibb (BMS)/AstraZeneca Pharmaceuticals (AZ). Leptin is supplied by BMS/AZ, and is currently
      only available through research studies. Neither the NIH nor BMS/AZ can guarantee that leptin
      will be available indefinitely and/or after the study ends. However, leptin was recently
      approved by the FDA on February 25, 2014, for use in patients with generalized lipodystrophy.

      All patient referrals for acceptance into the protocol, are initiated by the physician/health
      care provider.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Percentage of glycosylated hemoglobin at Baseline, 6 months, and 12 months on treatment with metreleptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Metreleptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metreleptin</intervention_name>
    <description>Drug treatment</description>
    <arm_group_label>Metreleptin</arm_group_label>
    <other_name>Leptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        All ethnic groups.

        Males and females.

          -  Age greater than or equal to 6 months.

          -  Clinically significant lipodystrophy, identified by the study physician during the
             physical examination as an absence of fat outside the range of normal variation and/or
             identified as a disfiguring factor by the patient.

        Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males
        as measured by Linco assay on a specimen obtained after an overnight fast. In children ages
        6 months 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin
        samples will be run through Millipore Laboratories, who use the Linco Assay, which has been
        the assay previously used to measure leptin levels throughout this study period.

        Presence of at least one of the following metabolic abnormalities:

          1. Presence of diabetes as defined by the 2007 ADA criteria

               1. Fasting plasma glucose greater than or equal to 126 mg/dL, or

               2. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram
                  (1.75gm/kg) oral glucose load, or

               3. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl

          2. Fasting insulin greater than 30 micro units/ml.

          3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated
             triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in
             infants)

             -Persons with impaired decision-making capacity and who may be unable to provide
             informed consent may participate in this study per the discretion of the Principal
             Investigator.

             EXCLUSION CRITERIA:

             Pregnant women, women in their reproductive years who do not use an effective method
             of birth control, and women currently nursing or lactating within 6 weeks of having
             completed nursing.

             Exclusions for underlying diseases likely to increase side effects or hinder objective
             data collection:

               -  Known infectious liver disease

               -  Known HIV infection

               -  Current alcohol or substance abuse

               -  Psychiatric disorder impeding competence or compliance

               -  Active tuberculosis

               -  Use of anorexiogenic drugs

               -  Other condition(s) which in the opinion of the clinical investigators would
                  impede completion of the study

               -  Subjects who have known hypersensitivity to E. Coli derived proteins.

               -  Subjects with acquired lipodystrophy and a hematologic abnormality such as
                  neutropenia and/or lymphadenopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Gorden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-DK-0022.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest. 1997 Dec 1;100(11):2900-8.</citation>
    <PMID>9389757</PMID>
  </reference>
  <reference>
    <citation>Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Dev. 1998 Oct 15;12(20):3168-81.</citation>
    <PMID>9784492</PMID>
  </reference>
  <reference>
    <citation>Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000 Jan 1;9(1):109-12.</citation>
    <PMID>10587585</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2001</study_first_submitted>
  <study_first_submitted_qc>October 27, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2001</study_first_posted>
  <results_first_submitted>March 1, 2016</results_first_submitted>
  <results_first_submitted_qc>August 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2016</results_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoatrophic Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>NASH</keyword>
  <keyword>Lipodystrophy</keyword>
  <keyword>Leptin</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metreleptin</title>
          <description>subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Generalized Lipodystrophy</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Partial Lipodystrophy</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>had atypical progeriod lipodystrophy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no baseline data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>didn't reach 6 months of Metreleptin</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metreleptin With Generalized Lipodystrophy</title>
          <description>patients with generalized lipodystrophy with subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
        </group>
        <group group_id="B2">
          <title>Metreleptin With Patial Lipodystrophy</title>
          <description>patients with partial lipodystrophy with subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="12"/>
                    <measurement group_id="B2" value="35" spread="14"/>
                    <measurement group_id="B3" value="24" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric patients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>aged &lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aged &gt;=20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index-standard deviation score (BMI-SDS)</title>
          <description>Body mass index -standard deviation score (BMI-SDS) represents a measure of weight, adjusted for height, sex, and age. sample range of BMI-SDS is (-3.23, 1.91). Higher value indicates more body fat.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.26" spread="0.98"/>
                    <measurement group_id="B2" value="0.66" spread="0.7"/>
                    <measurement group_id="B3" value="0.41" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage body fat</title>
          <description>percentage of body fat</description>
          <units>percentage of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" spread="2"/>
                    <measurement group_id="B2" value="22" spread="4"/>
                    <measurement group_id="B3" value="15" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leptin</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" spread="0.74"/>
                    <measurement group_id="B2" value="6.23" spread="3.96"/>
                    <measurement group_id="B3" value="3.03" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180" spread="80"/>
                    <measurement group_id="B2" value="182" spread="87"/>
                    <measurement group_id="B3" value="181" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="2.3"/>
                    <measurement group_id="B2" value="8.1" spread="2.2"/>
                    <measurement group_id="B3" value="8.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting insulin</title>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122" spread="318"/>
                    <measurement group_id="B2" value="82" spread="157"/>
                    <measurement group_id="B3" value="108" spread="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.61" spread="4.03"/>
                    <measurement group_id="B2" value="3.56" spread="2.27"/>
                    <measurement group_id="B3" value="4.82" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antidiabetic medications per patient</title>
          <units>antidiabetic medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" spread="0.7"/>
                    <measurement group_id="B2" value="1.79" spread="0.68"/>
                    <measurement group_id="B3" value="1.36" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin users</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not known</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid-lowering medications per patient</title>
          <units>lipid-lowering medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.61" spread="0.84"/>
                    <measurement group_id="B2" value="1.07" spread="1.04"/>
                    <measurement group_id="B3" value="0.82" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214" spread="110"/>
                    <measurement group_id="B2" value="235" spread="147"/>
                    <measurement group_id="B3" value="222" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="467" lower_limit="200" upper_limit="847"/>
                    <measurement group_id="B2" value="483" lower_limit="232" upper_limit="856"/>
                    <measurement group_id="B3" value="473" lower_limit="200" upper_limit="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C</title>
          <description>high-density lipoprotein cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="9"/>
                    <measurement group_id="B2" value="31" spread="9"/>
                    <measurement group_id="B3" value="30" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C</title>
          <description>low-density lipoprotein cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104" spread="50"/>
                    <measurement group_id="B2" value="101" spread="36"/>
                    <measurement group_id="B3" value="103" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin A</title>
          <units>µg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="33"/>
                    <measurement group_id="B2" value="73" spread="20"/>
                    <measurement group_id="B3" value="61" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin E</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="32"/>
                    <measurement group_id="B2" value="34" spread="21"/>
                    <measurement group_id="B3" value="31" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-Hydroxyvitamin D</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="11"/>
                    <measurement group_id="B2" value="23" spread="13"/>
                    <measurement group_id="B3" value="19" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PT</title>
          <description>prothrombin time</description>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="1.2"/>
                    <measurement group_id="B2" value="13.2" spread="0.6"/>
                    <measurement group_id="B3" value="13.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Normalized Ratio (INR)</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.10" spread="0.14"/>
                    <measurement group_id="B2" value="0.98" spread="0.06"/>
                    <measurement group_id="B3" value="1.05" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily total insulin units per patient</title>
          <units>insulin units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="625" spread="1099"/>
                    <measurement group_id="B2" value="278" spread="214"/>
                    <measurement group_id="B3" value="362" spread="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</title>
        <description>Percentage of glycosylated hemoglobin at Baseline, 6 months, and 12 months on treatment with metreleptin</description>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Generalized Lipodystrophy (GLD)</title>
            <description>patients with generalized lipodystrophy (GLD) with initiation of subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
          </group>
          <group group_id="O2">
            <title>Partial Lipodystrophy (PLD)</title>
            <description>patients with partial lipodystrophy (PLD) with initiation of subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</title>
          <description>Percentage of glycosylated hemoglobin at Baseline, 6 months, and 12 months on treatment with metreleptin</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.3"/>
                    <measurement group_id="O2" value="8.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="1.7"/>
                    <measurement group_id="O2" value="7.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.5"/>
                    <measurement group_id="O2" value="7.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A null hypothesis of interest is there is no significant change over three time points (baseline, 6 months, 12 months) in response to metreleptin within GLD group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A null hypothesis of interest is there is no significant change over three time points (baseline, 6 months, 12 months) in response to metreleptin within PLD group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</title>
        <time_frame>Baseline, 6 months, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Generalized Lipodystrophy (GLD)</title>
            <description>patients with generalized lipodystrophy (GLD) with initiation of subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
          </group>
          <group group_id="O2">
            <title>Partial Lipodystrophy (PLD)</title>
            <description>patients with partial lipodystrophy (PLD) with initiation of subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin</title>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467" lower_limit="200" upper_limit="847"/>
                    <measurement group_id="O2" value="483" lower_limit="232" upper_limit="856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="122" upper_limit="283"/>
                    <measurement group_id="O2" value="339" lower_limit="211" upper_limit="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="106" upper_limit="312"/>
                    <measurement group_id="O2" value="326" lower_limit="175" upper_limit="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Triglycerides were log transformed for analysis due to non-normal distribution. Changes in triglycedies in response to metreleptin over three time points (baseline, 6 months, 12 months) are tested within GLD group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Triglycerides were log transformed for analysis due to non-normal distribution. Changes in triglycedies in response to metreleptin over three time points (baseline, 6 months, 12 months) are tested within PLD group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metreleptin</title>
          <description>subcutaneous metreleptin injection (0.06-0.24 mg/kg/day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbations of heart failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain requiring hospitalization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Acute exacerbation of pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Severe acute bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Group B streptococcus bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst requiring bilateral oophorectomy and total abdominal hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Miscarriage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Joins pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>tumor, benign</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Phillip Gorden</name_or_title>
      <organization>National Institute of DIabetes and Digestive and Kidney Dseases, National Institutes of Health</organization>
      <phone>301-402-7340</phone>
      <email>phillipg@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

